收费全文 | 185篇 |
免费 | 12篇 |
财政金融 | 39篇 |
工业经济 | 4篇 |
计划管理 | 41篇 |
经济学 | 50篇 |
运输经济 | 4篇 |
旅游经济 | 7篇 |
贸易经济 | 29篇 |
农业经济 | 12篇 |
经济概况 | 11篇 |
2023年 | 2篇 |
2021年 | 1篇 |
2020年 | 3篇 |
2019年 | 7篇 |
2018年 | 4篇 |
2017年 | 11篇 |
2016年 | 13篇 |
2015年 | 7篇 |
2014年 | 10篇 |
2013年 | 35篇 |
2012年 | 5篇 |
2011年 | 7篇 |
2010年 | 5篇 |
2009年 | 13篇 |
2008年 | 13篇 |
2007年 | 11篇 |
2006年 | 5篇 |
2005年 | 4篇 |
2004年 | 1篇 |
2003年 | 5篇 |
2002年 | 5篇 |
2001年 | 5篇 |
2000年 | 1篇 |
1999年 | 2篇 |
1998年 | 6篇 |
1997年 | 1篇 |
1996年 | 6篇 |
1989年 | 3篇 |
1988年 | 1篇 |
1986年 | 1篇 |
1980年 | 2篇 |
1977年 | 1篇 |
1975年 | 1篇 |
Methods: The Treat-to-Target strategy consisted of a systematic switch to second-line tumor necrosis factor (TNF)α inhibitor in case of an unmet ACR50 response at 3 months compared to current routine clinical practice. A reference cohort treated first-line with certolizumab pegol according to current practice without systematic switching was considered as the comparator. A decision-tree model was constructed to estimate clinical outcome (health assessment questionnaire-disability index or HAQ-DI score), time spent in ACR50 response (ACR 50), and direct costs of treatment over a 2-year period. HAQ scores were derived from American College of Rheumatology 50 (ACR50) responses. All TNFα inhibitors were assumed to have equivalent efficacy and tolerability. Costs were estimated at 2013 French retail prices (date of the pay-for-performance agreement).
Results: The mean duration of an ACR50 response was 1.23 years in the Treat-to-Target strategy certolizumab pegol cohort vs 0.98 years in the reference cohort, resulting in a mean gain in HAQ at 24 months of 0.117. The Treat-to-Target strategy with a mix of TNFα inhibitors as second-line therapy was more expensive than the reference strategy in absolute terms, but this difference was entirely offset by the pay-for-performance agreement. The Treat-to-Target strategy was, thus, cost-neutral over a 2-year period after the payback of CZP cost for patients not achieving the target at 3 months.
Conclusions: In the context of a pay-for-performance agreement, the management of patients with rheumatoid arthritis using a Treat-to-Target strategy with certolizumab pegol in first line is dominant compared to standard use of this drug in the French setting in 2013. 相似文献
Large established farmers are those who stand to lose the most from our proposals. However, they and those who represent them have to face the inefficiencies of the current policy and society's demands. Farmers deserve rewards from public funds for the rural public goods they provide, but these rewards should be decoupled and targeted. A profound reform is required if we are to preserve a 'European model of the countryside'. 相似文献